Tris Pharma expands retrieval of potentially dangerous infants' ibuprofen

Tris Pharma
Tris pharma has expanded a recall of a drug for infants. (Tris Pharma)

Tris Pharma, which first recalled potentially harmful infants' ibuprofen in December, is adding lots to the recall.

The New Jersey-based company, which in December began a recall to the consumer level of three lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP 50 mg per 1.25 mL, has now added three more lots to the effort. The products were sold in Walmart, CVS and Family Dollar stores

The product was produced by its Tris Pharma unit, whose plant in Monmouth Junction, New Jersey, was slapped last year with an FDA warning letter for its lack of urgency about investigating product failures.

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: Tris Pharma, a CMO for Pfizer, hit with FDA warning letter for ADHD drug, morphine solution

The drugmaker has said there is a remote possibility that infants “susceptible to a higher potency level of drug” could end up with permanent kidney damage from the nonsteroidal anti-inflammatory drug. Tris has not received any reports of adverse events, but reactions can include nausea, vomiting and stomach pain.

Nearly a year ago, the FDA criticized the Tris manufacturing facility in New Jersey for the company's inadequate investigation of defect complaints and product failures. The agency said Tris “lacked thorough investigations into root causes, and failed to implement prompt and effective corrective actions and preventative actions.”

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.